IGF-1 and Cardiometabolic Diseases: a Mendelian Randomisation Study

Overview

Journal Diabetologia

Specialty Endocrinology

Date 2020 Jun 18

PMID 32548700

Citations 26

Authors

Susanna C Larsson

Karl Michaelsson

Stephen Burgess

Affiliations

Soon will be listed here.

Abstract

Aims/hypothesis: Abnormal serum IGF-1 levels are associated with an increased risk of type 2 diabetes and cardiovascular disease. However, the causal role of IGF-1 levels within the normal range in cardiometabolic disease remains unclear. We employed Mendelian randomisation to explore the associations between genetically predicted serum IGF-1 levels and cardiometabolic diseases.

Methods: Serum IGF-1 levels were predicted using 416 SNPs associated with IGF-1 levels among 358,072 individuals in UK Biobank. Genetic association estimates for the outcomes were obtained from consortia of type 2 diabetes (74,124 cases, 824,006 controls), coronary artery disease (60,801 cases, 123,504 controls), heart failure (47,309 cases, 930,014 controls), atrial fibrillation (65,446 cases, 522,744 controls), and ischaemic stroke (60,341 cases, 454,450 controls).

Results: Genetic predisposition to elevated serum IGF-1 levels was associated with higher risk of type 2 diabetes and coronary artery disease. The OR (95% CI) per SD increment in IGF-1 level was 1.14 (1.05, 1.24) for type 2 diabetes and 1.09 (1.02, 1.16) for coronary artery disease. The association between IGF-1 and coronary artery disease was attenuated after adjustment for type 2 diabetes (OR 1.06 [95% CI 1.00, 1.13]), suggesting that the association may be partly mediated via type 2 diabetes. There was limited evidence of associations between IGF-1 levels and heart failure, atrial fibrillation and ischaemic stroke.

Conclusions/interpretation: This study found evidence that increased IGF-1 levels may be causally associated with higher risk of type 2 diabetes. Graphical abstract.

Citing Articles

The association between IGF-1 levels and four types of osteoarthritis: a bidirectional and two-step mendelian randomization study.

Pan X, Cheng M, Li D, Liu Z, Yao Q, Jiang W Front Genet. 2024; 15:1366138.

PMID: 39050250 PMC: 11266086. DOI: 10.3389/fgene.2024.1366138.

IGF-1 and IGFBP-1 as Possible Predictors of Response to Lifestyle Intervention-Results from Randomized Controlled Trials.

Meyer N, Kabisch S, Dambeck U, Honsek C, Kemper M, Gerbracht C Int J Mol Sci. 2024; 25(12).

PMID: 38928106 PMC: 11203659. DOI: 10.3390/ijms25126400.

Using genetics and proteomics data to identify proteins causally related to COVID-19, healthspan and lifespan: a Mendelian randomization study.

Zhao J, Yao M, Liu Z Aging (Albany NY). 2024; 16(7):6384-6416.

PMID: 38575325 PMC: 11042960. DOI: 10.18632/aging.205711.

The Role of p53 in Regulating Chronic Inflammation and PANoptosis in Diabetic Wounds.

He W, Tang M, Gu R, Wu X, Mu X, Nie X Aging Dis. 2024; .

PMID: 38377027 PMC: 11745441. DOI: 10.14336/AD.2024.0212.

Mendelian randomization analysis demonstrates the causal effects of IGF family members in diabetes.

Li X, Tang J, Lin S, Liu X, Li Y Front Med (Lausanne). 2024; 11:1332162.

PMID: 38375323 PMC: 10875044. DOI: 10.3389/fmed.2024.1332162.

References

Scott R, Lagou V, Welch R, Wheeler E, Montasser M, Luan J . Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. Nat Genet. 2012; 44(9):991-1005. PMC: 3433394. DOI: 10.1038/ng.2385. View

Lombardi G, Di Somma C, Grasso L, Savanelli M, Colao A, Pivonello R . The cardiovascular system in growth hormone excess and growth hormone deficiency. J Endocrinol Invest. 2012; 35(11):1021-9. DOI: 10.3275/8717. View

Simila M, Kontto J, Virtamo J, Hatonen K, Valsta L, Sundvall J . Insulin-like growth factor I, binding proteins -1 and -3, risk of type 2 diabetes and macronutrient intakes in men. Br J Nutr. 2019; 121(8):938-944. DOI: 10.1017/S0007114519000321. View

Hemani G, Zheng J, Elsworth B, Wade K, Haberland V, Baird D . The MR-Base platform supports systematic causal inference across the human phenome. Elife. 2018; 7. PMC: 5976434. DOI: 10.7554/eLife.34408. View

Burgess S, Bowden J, Fall T, Ingelsson E, Thompson S . Sensitivity Analyses for Robust Causal Inference from Mendelian Randomization Analyses with Multiple Genetic Variants. Epidemiology. 2016; 28(1):30-42. PMC: 5133381. DOI: 10.1097/EDE.0000000000000559. View

Kaplan R, McGinn A, Pollak M, Kuller L, Strickler H, Rohan T . Association of total insulin-like growth factor-I, insulin-like growth factor binding protein-1 (IGFBP-1), and IGFBP-3 levels with incident coronary events and ischemic stroke. J Clin Endocrinol Metab. 2007; 92(4):1319-25. DOI: 10.1210/jc.2006-1631. View

Yavorska O, Burgess S . MendelianRandomization: an R package for performing Mendelian randomization analyses using summarized data. Int J Epidemiol. 2017; 46(6):1734-1739. PMC: 5510723. DOI: 10.1093/ije/dyx034. View

Hannon A, Thompson C, Sherlock M . Diabetes in Patients With Acromegaly. Curr Diab Rep. 2017; 17(2):8. DOI: 10.1007/s11892-017-0838-7. View

Johnsen S, Hundborg H, Sorensen H, Orskov H, Tjonneland A, Overvad K . Insulin-like growth factor (IGF) I, -II, and IGF binding protein-3 and risk of ischemic stroke. J Clin Endocrinol Metab. 2005; 90(11):5937-41. DOI: 10.1210/jc.2004-2088. View

10.

Larsson S, Wolk K, Brismar K, Wolk A . Association of diet with serum insulin-like growth factor I in middle-aged and elderly men. Am J Clin Nutr. 2005; 81(5):1163-7. DOI: 10.1093/ajcn/81.5.1163. View

11.

Ruidavets J, Luc G, Machez E, Genoux A, Kee F, Arveiler D . Effects of insulin-like growth factor 1 in preventing acute coronary syndromes: the PRIME study. Atherosclerosis. 2011; 218(2):464-9. DOI: 10.1016/j.atherosclerosis.2011.05.034. View

12.

Juul A, Scheike T, Davidsen M, Gyllenborg J, Jorgensen T . Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation. 2002; 106(8):939-44. DOI: 10.1161/01.cir.0000027563.44593.cc. View

13.

Wood A, Esko T, Yang J, Vedantam S, Pers T, Gustafsson S . Defining the role of common variation in the genomic and biological architecture of adult human height. Nat Genet. 2014; 46(11):1173-86. PMC: 4250049. DOI: 10.1038/ng.3097. View

14.

Shungin D, Winkler T, Croteau-Chonka D, Ferreira T, Locke A, Magi R . New genetic loci link adipose and insulin biology to body fat distribution. Nature. 2015; 518(7538):187-196. PMC: 4338562. DOI: 10.1038/nature14132. View

15.

Scott R, Scott L, Magi R, Marullo L, Gaulton K, Kaakinen M . An Expanded Genome-Wide Association Study of Type 2 Diabetes in Europeans. Diabetes. 2017; 66(11):2888-2902. PMC: 5652602. DOI: 10.2337/db16-1253. View

16.

Ricketts S, Rensing K, Holly J, Chen L, Young E, Luben R . Prospective study of insulin-like growth factor-I, insulin-like growth factor-binding protein 3, genetic variants in the IGF1 and IGFBP3 genes and risk of coronary artery disease. Int J Mol Epidemiol Genet. 2011; 2(3):261-85. PMC: 3166154. View

17.

Friedrich N, Thuesen B, Jorgensen T, Juul A, Spielhagen C, Wallaschofksi H . The association between IGF-I and insulin resistance: a general population study in Danish adults. Diabetes Care. 2012; 35(4):768-73. PMC: 3308317. DOI: 10.2337/dc11-1833. View

18.

Lawlor D, Ebrahim S, Davey Smith G, Cherry L, Watt P, Sattar N . The association of insulin-like-growth factor 1 (IGF-1) with incident coronary heart disease in women: findings from the prospective British Women's Heart and Health Study. Atherosclerosis. 2008; 201(1):198-204. DOI: 10.1016/j.atherosclerosis.2007.12.061. View

19.

Bo Y, Liu C, Ji Z, Yang R, An Q, Zhang X . A high whey protein, vitamin D and E supplement preserves muscle mass, strength, and quality of life in sarcopenic older adults: A double-blind randomized controlled trial. Clin Nutr. 2018; 38(1):159-164. DOI: 10.1016/j.clnu.2017.12.020. View

20.

Roselli C, Chaffin M, Weng L, Aeschbacher S, Ahlberg G, Albert C . Multi-ethnic genome-wide association study for atrial fibrillation. Nat Genet. 2018; 50(9):1225-1233. PMC: 6136836. DOI: 10.1038/s41588-018-0133-9. View